• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长春新碱和长春碱的脑摄取及抗癌活性受其在大鼠体内脑血管通透性低和与血浆成分结合的限制。

Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

作者信息

Greig N H, Soncrant T T, Shetty H U, Momma S, Smith Q R, Rapoport S I

机构信息

Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892.

出版信息

Cancer Chemother Pharmacol. 1990;26(4):263-8. doi: 10.1007/BF02897227.

DOI:10.1007/BF02897227
PMID:2369790
Abstract

Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an isolated, in situ brain perfusion technique. Drug binding to plasma constituents was also measured. Despite the high lipophilicity of these agents (the log octanol/physiological saline partition coefficient equalled 2.14 and 1.68, respectively), the cerebrovascular permeability-surface area product, PA, of vincristine in plasma was only 0.49 x 10(-4) ml s-1 g-1 for parietal cerebral cortex, whereas that of vinblastine was too low for determination. These values are similar to those of water-soluble, poorly diffusible nonelectrolytes. The PAs were significantly higher in the absence of plasma protein, being 1.24 x 10(-4) and 5.36 x 10(-4) ml s-1 g-1, respectively. Even these values, determined by brain perfusion of protein-free buffer, were lower than would be expected from the lipophilicity of the agents. The results suggest that additional factors, such as steric hindrance and molecular charge distribution, related to the chemical and geometric structure and the large size of vincristine and vinblastine (molecular weight, 825 and 814 daltons, respectively) restrict their passage across the blood-brain barrier. As a consequence of their paradoxically low permeability at the blood-brain barrier and restrictive binding to plasma and blood constituents, doses of both agents that cause significant inhibition of extracerebral Walker 256 carcinosarcoma tumor implants in rat have no effect on tumor located in the brain.

摘要

采用离体原位脑灌注技术,在麻醉大鼠中研究了亲脂性抗癌药物长春新碱和长春碱的单向血脑屏障转运。还测定了药物与血浆成分的结合情况。尽管这些药物具有高亲脂性(正辛醇/生理盐水分配系数的对数值分别为2.14和1.68),但长春新碱在血浆中的脑血管通透表面积乘积PA,对于顶叶大脑皮层仅为0.49×10⁻⁴ ml s⁻¹ g⁻¹,而长春碱的该值过低无法测定。这些数值与水溶性、扩散性差的非电解质相似。在没有血浆蛋白时,PA值显著更高,分别为1.24×10⁻⁴和5.36×10⁻⁴ ml s⁻¹ g⁻¹。即使是通过无蛋白缓冲液脑灌注测定的这些数值,也低于根据药物亲脂性预期的值。结果表明,与长春新碱和长春碱的化学和几何结构以及大尺寸(分子量分别为825和814道尔顿)相关的其他因素,如空间位阻和分子电荷分布,限制了它们通过血脑屏障。由于它们在血脑屏障处的通透性反常地低以及与血浆和血液成分的结合受限,在大鼠中能显著抑制脑外Walker 256癌肉瘤肿瘤植入的这两种药物剂量,对位于脑内的肿瘤没有作用。

相似文献

1
Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.长春新碱和长春碱的脑摄取及抗癌活性受其在大鼠体内脑血管通透性低和与血浆成分结合的限制。
Cancer Chemother Pharmacol. 1990;26(4):263-8. doi: 10.1007/BF02897227.
2
Opening the blood-brain and blood-tumor barriers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow.打开实验性大鼠脑肿瘤中的血脑屏障和血肿瘤屏障:颈内动脉高渗甘露醇对毛细血管通透性和血流的影响。
Ann Neurol. 1986 Jan;19(1):50-9. doi: 10.1002/ana.410190110.
3
An in situ brain perfusion technique to study cerebrovascular transport in the rat.一种用于研究大鼠脑血管转运的原位脑灌注技术。
Am J Physiol. 1984 Sep;247(3 Pt 2):H484-93. doi: 10.1152/ajpheart.1984.247.3.H484.
4
Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.环磷酰胺和磷酰胺芥在大鼠体内的脑和血浆药代动力学及抗癌活性
Cancer Chemother Pharmacol. 1990;27(1):1-7. doi: 10.1007/BF00689268.
5
Regional cerebrovascular transport of leucine as measured by the in situ brain perfusion technique.通过原位脑灌注技术测量的亮氨酸的区域脑血管转运。
J Cereb Blood Flow Metab. 1985 Jun;5(2):300-11. doi: 10.1038/jcbfm.1985.39.
6
Changes of the blood-brain barrier in experimental metastatic brain tumors.实验性转移性脑肿瘤中血脑屏障的变化
J Neurosurg. 1983 Aug;59(2):304-10. doi: 10.3171/jns.1983.59.2.0304.
7
Permeability characteristics of brain adjacent to tumors in rats.
Arch Neurol. 1975 Dec;32(12):785-91. doi: 10.1001/archneur.1975.00490540029003.
8
Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats.新型多药耐药逆转剂环孢素SDZ PSC 833在大鼠体内的脑渗透呈剂量依赖性。
Cancer Chemother Pharmacol. 1996;38(5):481-6. doi: 10.1007/s002800050515.
9
Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine.P-糖蛋白在秋水仙碱和长春碱血脑转运中的作用。
J Neurochem. 1996 Oct;67(4):1688-93. doi: 10.1046/j.1471-4159.1996.67041688.x.
10
Modulating blood-brain barrier interactions of amino acid-based anticancer agents.调节氨基酸类抗癌药物的血脑屏障相互作用。
Drug Deliv. 2000 Jan-Mar;7(1):21-5. doi: 10.1080/107175400266759.

引用本文的文献

1
Inadvertent intrathecal application of vindesine and its neurological outcome: case report and systematic review of the literature.长春地辛意外鞘内注射及其神经学转归:病例报告及文献系统综述
Brain Spine. 2025 Jun 2;5:104292. doi: 10.1016/j.bas.2025.104292. eCollection 2025.
2
Evaluation of Drug Blood-Brain-Barrier Permeability Using a Microfluidic Chip.使用微流控芯片评估药物的血脑屏障通透性
Pharmaceutics. 2024 Apr 23;16(5):574. doi: 10.3390/pharmaceutics16050574.
3
Novel Brain-Penetrant, Small-Molecule Tubulin Destabilizers for the Treatment of Glioblastoma.

本文引用的文献

1
Pharmacokinetics of vincristine in the cerebrospinal fluid of subhuman primates.长春新碱在非人灵长类动物脑脊液中的药代动力学。
Cancer Res. 1980 Mar;40(3):722-4.
2
Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer.长春地辛、长春新碱和长春花碱在癌症患者中的比较药代动力学。
Cancer Treat Rev. 1980 Sep;7 Suppl 1:17-24. doi: 10.1016/s0305-7372(80)80003-x.
3
Pharmacokinetics of vincristine infusion.
Cancer Treat Rep. 1981 Nov-Dec;65(11-12):1043-8.
用于治疗胶质母细胞瘤的新型脑渗透性小分子微管解聚剂
Biomedicines. 2024 Feb 9;12(2):406. doi: 10.3390/biomedicines12020406.
4
Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience.成人髓母细胞瘤的临床特征及一线治疗对预后的影响;MD安德森癌症中心的经验
Neurooncol Adv. 2021 Jun 22;3(1):vdab079. doi: 10.1093/noajnl/vdab079. eCollection 2021 Jan-Dec.
5
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.在胶质母细胞瘤患者来源异种移植(GBM PDX)异种移植中进行临床前模型构建,以指导新型肿瘤检查点控制器利沙万布林(靶向微管)的临床开发。
Neuro Oncol. 2022 Mar 12;24(3):384-395. doi: 10.1093/neuonc/noab162.
6
Modulation of Blood-Brain Barrier Permeability by Activating Adenosine A2 Receptors in Oncological Treatment.激活肿瘤治疗中的腺苷 A2 受体调节血脑屏障通透性。
Biomolecules. 2021 Apr 24;11(5):633. doi: 10.3390/biom11050633.
7
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.高危低级别胶质瘤的放化疗:替莫唑胺与 PCV 的选择。
Cancer Med. 2020 Jan;9(1):3-11. doi: 10.1002/cam4.2686. Epub 2019 Nov 7.
8
6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.6-MOMIPP,一种新型脑穿透性抗有丝分裂吲哚查尔酮,可抑制神经胶质瘤的生长和活力。
Cancer Chemother Pharmacol. 2019 Feb;83(2):237-254. doi: 10.1007/s00280-018-3726-1. Epub 2018 Nov 13.
9
Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.替莫唑胺和洛莫司汀化疗治疗 MGMT 启动子甲基化的复发性胶质母细胞瘤。
J Korean Med Sci. 2018 May 10;33(24):e167. doi: 10.3346/jkms.2018.33.e167. eCollection 2018 Jun 11.
10
Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.在非小细胞肺癌治疗中使用 EGFR-TKI 的联合策略:从临床前结果与临床结局之间的差距中学习。
Int J Biol Sci. 2018 Feb 5;14(2):204-216. doi: 10.7150/ijbs.22955. eCollection 2018.
4
The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.长春碱在正常受试者和霍奇金病患者血清中的蛋白结合情况。
Eur J Clin Pharmacol. 1983;24(5):683-7. doi: 10.1007/BF00542223.
5
Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys.长春新碱、长春碱和长春地辛在恒河猴体内的药代动力学
Cancer Chemother Pharmacol. 1984;12(1):31-5. doi: 10.1007/BF00255905.
6
Blood-brain barrier integrity and host responses in experimental metastatic brain tumours.实验性转移性脑肿瘤中的血脑屏障完整性与宿主反应
Clin Exp Metastasis. 1983 Jul-Sep;1(3):229-46. doi: 10.1007/BF00736407.
7
An in situ brain perfusion technique to study cerebrovascular transport in the rat.一种用于研究大鼠脑血管转运的原位脑灌注技术。
Am J Physiol. 1984 Sep;247(3 Pt 2):H484-93. doi: 10.1152/ajpheart.1984.247.3.H484.
8
Chemotherapy of brain metastases: current status.脑转移瘤的化疗:现状
Cancer Treat Rev. 1984 Jun;11(2):157-86. doi: 10.1016/0305-7372(84)90006-9.
9
Neurotoxicity of vincristine after the osmotic opening of the blood-brain barrier.
Neuropathol Appl Neurobiol. 1983 Sep-Oct;9(5):345-54. doi: 10.1111/j.1365-2990.1983.tb00120.x.
10
Neurotoxicity of antineoplastic drugs.抗肿瘤药物的神经毒性
Semin Oncol. 1982 Mar;9(1):103-30.